Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy

NCT07268833 is registered in ClinicalTrials.gov with Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta as lead sponsor.

NCT NCT07268833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07268833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase
Observational
Overall status
Recruiting
Start date
October 24, 2024
Completion date
April 30, 2027
Enrollment
400 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als), peripheral neuropathies